Search is Powered by Google
HIV / AIDS News

GSK To Reduce Cost Of 14 Antiretrovirals Sold In Developing Nations

Main Category: HIV / AIDS
Also Included In: Pharma Industry / Biotech Industry
Article Date: 21 Feb 2008 - 6:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

GlaxoSmithKline on Tuesday announced that it is reducing by an average of 21% the cost of 14 of its antiretroviral drugs currently sold at not-for-profit prices in developing countries, the Wall Street Journal reports (Whalen, Wall Street Journal, 2/19).

The company in a statement said the most significant decrease is an almost 40% price reduction of its antiretroviral Ziagen. Ziagen has been recommended by the World Health Organization as a first- and second-line treatment, particularly among children (Kahn, Reuters, 2/19). The antiretroviral will cost about $15 per pack, or about 50 cents daily, GSK said. The company also announced that its most expensive antiretroviral, Lexiva, will be reduced by 20% to $3.35 daily. According to the Journal, GSK sells antiretrovirals at cost in 64 developing countries. The company said improvements in manufacturing and the availability of less expensive raw ingredients have allowed it to lower the prices (Wall Street Journal, 2/19).

GSK said the price reductions "will take effect immediately for public sector customers and not-for-profit organizations in the least developed countries and sub-Saharan Africa," as well as other eligible countries (Reuters, 2/19).

GSK CEO Jean-Pierre Garnier has said that he "always wanted to have access [to drugs] as part of the DNA of the company." He added, "I never wanted to just close my eyes to the fact that 80% of the population won't be able to afford the drugs. Because that's that truth -- 80% of the market of pharmaceuticals comes from 20% of the worldwide population" (Wall Street Journal, 2/19).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

View drug information on Lexiva.





Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Schizophrenia

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader


HIV and Cholesterol image HIV and Cholesterol

Elevated cholesterol can occur as a side effect from HIV treatments. Hear how one person with HIV steps up to the challenge of getting his cholesterol down...

Fast and Easy HIV Testing image Fast and Easy HIV Testing

Tests that can rapidly detect HIV are an important advancement in the fight against HIV and AIDS. Will these fast and easy tests lead to greater screening...

View more videos...